Multiple Myeloma

Stringent Complete Response in Multiple Myeloma Associated With Best Survival Outcomes

Patients able to achieve stringent complete response after undergoing autologous stem-cell transplantation for multiple myeloma achieved improved long-term outcomes, including overall survival and time to progression, compared with patients who achieved lesser levels of response.

Multiple Myeloma

FDA Approves Front-Line Lenalidomide for Multiple Myeloma

Leah Lawrence

News | February 23, 2015 | Multiple Myeloma, Hematologic Malignancies

By Leah Lawrence

The FDA has expanded the use of oral lenalidomide in multiple myeloma to include its use in combination with dexamethasone for newly diagnosed patients.

Frailty Score Predicts Survival in Elderly Myeloma Patients

Leah Lawrence

News | February 03, 2015 | Multiple Myeloma, Hematologic Malignancies

By Leah Lawrence

A scoring system that measured frailty in elderly patients with multiple myeloma was able to accurately predict mortality and risk of toxicity.

Myeloma Working Group Releases Statement on Use of MRI

Leah Lawrence

News | January 23, 2015 | Multiple Myeloma, Hematologic Malignancies

By Leah Lawrence

The International Myeloma Working Group recently published a series of consensus statements discussing the use of MRI in the treatment of multiple myeloma.

Higher Bortezomib Dose Upped Multiple Myeloma Survival

Leah Lawrence

News | January 13, 2015 | Multiple Myeloma, Hematologic Malignancies

By Leah Lawrence

A new trial reported improved overall survival in myeloma patients who received a higher bortezomib dose as part of a bortezomib/melphalan/prednisone regimen.

Smoking Not a Risk Factor for Multiple Myeloma

Leah Lawrence

News | January 07, 2015 | Multiple Myeloma, Hematologic Malignancies

By Leah Lawrence

Cigarette smoking is not a risk factor for multiple myeloma, according to the results of a pooled analysis of nine case-control studies.

Daratumumab Safe With Myeloma Backbone Therapies

Leah Lawrence

News | December 16, 2014 | Multiple Myeloma, ASH 2014, Hematologic Malignancies

By Leah Lawrence

The addition of daratumumab to traditional therapies used in the treatment of multiple myeloma was well tolerated and associated with high rates of responses.